Trial Profile

Sequential Treatment Regimens With RO-MTX After Pomalidomide, Orelabrutinib, Rituximab (POR) as Frontline Therapy for Primary Central Nervous System Lymphoma: a Multicenter Prospective Single Arm Trial

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 28 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Methotrexate (Primary) ; Orelabrutinib (Primary) ; Pomalidomide (Primary) ; Rituximab (Primary)
Indications B-cell lymphoma; Brain cancer
Focus Therapeutic Use

15 Jun 2023 Results (n=13; data cutoff date: 15 Sep 2023) of preliminary data presented at the 28th Congress of the European Haematology Association
12 Jun 2023 Results presented in an InnoCare Pharma media release.
12 Jun 2023 According to an InnoCare Pharma media release, results from this study were presented at the European Hematology Association (EHA) 2023 Hybrid Congress.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com